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Abstract
Background -: Experimental studies have shown that ultrasound contrast agents enhance the effectiveness of
thrombolytic agents in the presence of ultrasound in vitro and in vivo. Recently, we have launched a clinical pilot study,
called "Sonolysis", to study this effect in patients with ST-elevation myocardial infarction based on proximal lesions of the
infarct-related artery.
Methods/design -: In our multicenter, randomized, placebo controlled clinical trial we will include patients between 18
and 80 years of age with their first ST-elevation myocardial infarction based on a proximal lesion of the infarct-related
artery. After receiving a single bolus alteplase 50 mg IV (Actilyse® Boehringer Ingelheim GmbH), a loading dose of aspirin
500 mg, and heparin 5000 IU in the ambulance according to the prehospital thrombolysis protocol, patients, following
oral informed consent, are randomized to undergo 15 minutes of pulsatile ultrasound with intravenous administration of
ultrasound contrast agent or placebo without ultrasound. Afterwards coronary angiography and, if indicated,
percutaneous coronary intervention will take place. A total of 60 patients will be enrolled in approximately 1 year.
The primary endpoints are based on the coronary angiogram and consist of TIMI flow, corrected TIMI frame count, and
myocardial blush grade. Follow-up includes 12-lead ECG, 2D-echocardiography, cardiac MRI, and enzyme markers to
obtain our secondary endpoints, including the infarct size, wall motion abnormalities, and the global left ventricular
function.
Discussion -: The Sonolysis study is the first multicenter, randomized, placebo controlled clinical trial investigating the
therapeutic application of ultrasound and microbubbles in acute ST-elevation myocardial infarction patients. A positive
finding may stimulate further research and technical innovations to implement the treatment in the ambulance and maybe
obtain even more patency at an earlier stage.
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Thrombo-occlusive cardiovascular disease is the leading
cause of mortality in the western world. Among these,
acute ST-elevation myocardial infarction (STEMI) is an
important disease with high morbidity and mortality. In
the course of years, two major treatment strategies have
been developed, aiming at immediate restoration of coro-
nary blood flow.
Currently, the first choice of treatment in patients with
acute STEMI is primary percutaneous coronary interven-
tion (PCI). However, its feasibility depends on the availa-
bility of equipment and trained personnel. As a result,
thrombolysis is worldwide the most commonly used ther-
apy for patients with STEMI[1]. Nevertheless, thromboly-
sis is known to have a relatively low recanalization rate
and is related to more haemorrhagic complications[2].
Hence, there is an ongoing search for a non-invasive and
easy applicable therapeutic strategy with less serious side-
effects, still based on the early restoration of coronary
blood flow.
One of the new non-invasive therapy strategies is the use
of ultrasound and an ultrasound contrast agent, in combi-
nation with thrombolysis[3,4].
Previous studies have indicated that ultrasound alone
may accelerate fibrinolysis[5]. The addition of microbub-
bles being destroyed by high pressure ultrasound leads to
an even greater increase of fibrinolysis. There are three
proposed mechanisms which lead to this increase. The
first is the occurrence of shear stress based on micro-jets
which are created after the destruction of the microbub-
bles by ultrasound[6]. The second mechanism is the gen-
eration of reactive oxygen species in endothelial cells[7].
The third proposed mechanism for the increase of fibri-
nolysis is temperature rise which also takes place after the
microbubbles collapse under influence of ultrasound[8].
Although the full mechanism remains to be resolved, the
application of ultrasound alone and ultrasound in combi-
nation with contrast agents have proven their value by
enhancing clot dissolution, by creating microholes in
fresh thrombi. Tachibana and Tachibana were among the
first to describe the effect of an ultrasound contrast agent
on fibrinolysis in vitro[9]. They added urokinase with
microbubbles (Albunex) and ultrasound, which led to a
significant increase in fibrinolysis. This result was con-
firmed by other in vitro studies in the course of years [10-
13] (Table 1).
Birnbaum et al. were among the first to conduct an in vivo
study[14]. They used rabbit iliofemoral arteries to exam-
ine the effect of ultrasound and microbubbles on fibrinol-
ysis, without using any fibrinolytics. The recanalization
rate in the artery treated with a combination of microbub-
bles and ultrasound was significantly higher compared to
the application of ultrasound or microbubbles alone.
Siegel et al. conducted an other in vivo study in rabbit ili-
ofemoral arteries[15]. They showed a significant increase
of fibrinolysis in the combination of streptokinase and
ultrasound compared to streptokinase alone. Adding
microbubbles did not made any difference, however the
combination of the three was still better then streptoki-
nase alone.
Other in vivo studies confirmed a higher recanalization
rate using ultrasound and microbubbles[16,17] (Table 1).
In 2004, the CLOTBUST investigators published results of
a multicenter phase II trial conducted in patients with
acute stroke[18]. They randomly assigned 126 patients to
receive continuous ultrasound or placebo following treat-
ment with intravenous t-PA (0.9 mg/kg with a maximum
of 90 mg) within 3 hours after the onset of symptoms. The
results within 2 hours after administration showed a sig-
nificant increase of complete recanalization in the ultra-
sound group compared to placebo. It also showed a
nonsignificant trend towards recovery from stroke, com-
pared with placebo.
Molina et al. conducted a trial in which they added micro-
bubbles on top of ultrasound and t-PA[19]. The addition
of microbubbles induced further enhancement of ultra-
sound augmented thrombolysis, leading to more com-
plete recanalization.
The first to conduct a study in which ultrasound and
thrombolytic therapy was combined in a small group of
STEMI patients were Cohen et al. They found no major
adverse events and regarding efficacy their outcome com-
pared favourably with historical data[20].
However, until now the combination of ultrasound, ultra-
sound contrast agents (UCA), and thrombolytic therapy
has never been tested in STEMI patients. Therefore, we
will perform the first study in a pilot design in patients
with STEMI, in which we compare the combination of
ultrasound and microbubbles with placebo after prehos-
pital thrombolysis.
Methods and design
Study design
Sonolysis is designed as a multicenter, randomized, pla-
cebo controlled clinical trial that will be conducted in the
VU University Medical Center Amsterdam, University
Medical Center Utrecht, and Radboud University
Nijmegen Medical Center.Page 2 of 7
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with an acute STEMI based on a proximal lesion. To make
sure that we deal with a blocked proximal major epicar-
dial coronary artery our inclusion criteria consist of a sum
of ST-elevation of 6 mm or more in combined leads and
1 mm or more ST-elevation in lead V3R when there is an
inferior infarct. The exclusion criteria are mentioned in
Table 2.
Patients are randomized in either a placebo group or a
group that receives the ultrasound contrast agent Luminity®.
Randomization will take place on announcement by the
ambulance of a patient with an eligible STEMI. This
announcement is done through the unique Lifenet sys-
tem. An ECG of a patient with chest pain is recorded by
ambulance personnel and sent to a computer in the coro-
nary care unit of the hospital. There, the cardiology resi-
dent on call consults the intervention cardiologist and
together they will check the ECG for the inclusion criteria.
If the patient is eligible for the study, the ambulance per-
sonnel will be informed. This all is summarised in a flow
chart (Figure 1)
Randomization will be done by opening a sealed enve-
lope containing the contrast agent Luminity® or saline
0.9%, the placebo.
Patients will be pre-treated in the ambulance with a load-
ing dose of aspirin 500 mg iv., heparin 5000 IU iv., and a
Table 1: Studies assessing the influence of microbubbles and ultrasound on thrombolysis
Author(s)/reference Microbubble Target in vivo/in vitro TL, US, MB US frequency Outcome
Tachibana and 
Tachibana[9]
Albumin MB (albunex) In vitro thrombus UK, US and MB 170 kHz, 0.5 W/cm2 Significantly increased 
thrombolysis with 
thrombolytics, US and MB
Kondo et al. [10] Air-filled MB with 
galactose/palmitic acid 
shell
In vitro white 
thrombus
t-PA, US and MB 10 MHz, 0.5–1.0 W/
cm2
Significant enhancement of 
thrombus reduction by MB
Nishioka et al. [11] DDFP In vitro and in vivo 
canine iliofemoral 
arteries
MB and US 20 kHz, 1.5 W/cm2 Increased clot disruption 
and recanalization with US 
and MB
Porter et al. [12] Air-filled MB/PESDA MB In vitro thrombus UK, US and MB 20 kHz, 40 W/cm2 Significant better 
thrombolysis of PESDA than 
air-MB. Optimal 
thrombolysis with UK and 
MB
Mizushige et al. [13] Albumin Shell, air-filled/
galactose shell air-filled/
DDFP-filled MB
In vitro thrombus t-PA, US, MB 10 MHz, 1.02 W/cm2 Thrombolysis was greatest 
in DDFP-MB-group
Birnbaum et al. [14] PESDA MB In vivo canine 
iliofemoral artery
US and MB Up to 160 W/cm2 Significant higher 
recanalization rate with MB
Siegel et al. [15] DDFP/PESDA In vivo rabit iliofemoral 
artery and canine LAD
SK, US, MB 20–37 kHz, 1.5–160 
W/cm2
Increased clot dissolution 
with US, MB and SK
Culp et al. [16] PESDA tagged with 
eptifibatide
In vivo pigs ascending 
pharyngeal artery
US and MB 1 MH, 2 W/cm2 Improvement of 
recanalization rate in 
eptifibatide tagged PESDA
Xie et al. [17] Definity In vivo canine femoral 
artery and vein
US and MB 1 MHz, 0.4–0.6 W/
cm2 and 10 W/cm2
Higher recanalization rates 
with MB and US compared 
to US alone
CLOTBUST 
investigators[18]
- In vivo middle cerebral 
artery Phase 2 trial
t-PA and US 2 MHz Ultrasound augments t-PA 
induced arterial 
recanalization
Molina et al. [19] Galactose MB (Levovist) In vivo middle cerebral 
artery phase 2 trial
t-PA, US, MB 2 MHz MB safely induces 
acceleration of US enhanced 
thrombolysis
Cohen et al. [20] - In vivo STEMI phase 2 
trial
rt-PA and US 27 kHz No major adverse events
MB = microbubble; US = ultrasound; TL = thrombolytic; (r)t-PA = (recombinant) tissue plasminogen activator; PESDA = perfluorocarbon-exposed 
sonicated dextrose albumin; UK = urokinase; DDFP = dodecafluoropentane; LAD = left artery descending; SK = streptokinase
Table 2: Exclusion criteria of the Sonolysis study
• Clinical instability
• Previous Q-wave myocardial infarction
• Contra indications alteplase (Table 3)
• Known pulmonary hypertension (> 90 mmHg)
• Known allergy of Luminity®Page 3 of 7
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Ingelheim GmbH). The latter will be administered in
approximately 3 minutes if there are no contra-indica-
tions (Table 3). This is in accordance with the prehospital
thrombolysis protocol[21,22].
To avoid any time delay, informed consent will be
obtained orally, prior to PCI at arrival in the hospital.
Written informed consent will be given after primary PCI
when the patient is in a stable clinical condition.
Flow chart of the study design, divided in a hospital and a pre- hospital partigure 1
Flow chart of the study design, divided in a hospital and a pre- hospital part.
Eligible acute infarct patients
ASA, Heparine and rTPA (single bolus)
Randomize
Microbubbles NaCl 0.9%
Ultrasound during infusion
PCI
Pre-
hospital
Hospital
No ultrasound
Treatment arm Control arm, 
“sham” like
Table 3: Contraindications alteplase.
• Reduced consciousness
• Paralysis
• Arterial hypertension (systolic pressure > 180 mmHg)
• Known or suspected haemorrhagic diathesis
• Possible pregnancy
• Any history of stroke
• In the past 3 months
&#x2218; Significant trauma
&#x2218; Major surgery
&#x2218; Haemoptysis
&#x2218; Documented ulcerative gastrointestinal disease
&#x2218; Manifest or recent severe or dangerous bleeding
• Allergy to streptokinase or t-PA
• Systolic blood pressure of less than 80 mmHg during more than 5 minutes with clinical symptoms of shockPage 4 of 7
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informed consent, either placebo (i.e. 50 ml saline 0.9%)
without ultrasound, or the ultrasound contrast agent
Luminity® during simultaneously pulsatile ultrasound
application.
We will use one flacon Luminity® of 1.5 ml which contains
225 microliter perflutren, a high-molecular-weight gas,
which increases the stability of the microbubbles. This
will be shaken in the Vialmix™ for 45 seconds, to produce
the microspheres. After that 48.5 ml of saline 0.9% will be
added to create a 50 ml milky white suspension. The sus-
pension or placebo will be administered intravenously in
15 minutes with an infusion rate of 200 ml/h.
Luminity® is registered in the Netherlands as a diagnostic
contrast agent to improve imaging quality during echocar-
diography. Most occurring complications are minor, like
headache (2.0%), flushing (1.0%), and back pain (0.9%).
Allergic reactions happen approximately in one of every
10.000 patients[23].
The dose of 1.5 ml Luminity® has been shown to be safe
and well tolerated. Thus, we expect no difference in
adverse events between both groups.
Endpoints
The primary endpoints of the study are TIMI flow grade,
corrected TIMI frame count, and myocardial blush grade,
to document the patency of the culprit vessel. All of these
are measured during coronary angiography pre-PCI.
Secondary endpoints are ST resolution based on a 12-lead
ECG registration during ultrasound, PCI and post-PCI,
infarct size derived from measurement of the marker
enzymes, and wall motion abnormalities (WMA) meas-
ured with 2D-echo and contrast enhanced MRI.
Cardiac imaging
The ultrasound equipment used in this protocol is the
Ie33 (Philips, Eindhoven, the Netherlands). In combina-
tion with a X3-1 probe we make 3D full volume images of
the aortic root in the parasternal short axis view to ensure
that the proximal parts of the epicardial coronary artery
system is encompassed within the target zone.
The mechanical index will be set on 1.18 in order to make
the microbubble collapse. The frequency we will use is 1.6
MHz intermittently (5 seconds on, 5 seconds off) to
ensure the microbubbles to enter the proximal portion of
the occluded coronary artery between the pulses.
During follow-up, a 2D echo will be performed to obtain
information about wall motion abnormalities, left ventri-
cle volumes, and ejection fraction.
The standard emergency coronary angiogram will be per-
formed to assess the patency of the culprit lesion, the TIMI
flow, the corrected TIMI frame count, and the myocardial
blush grade. To obtain the myocardial blush grade the
angiographic runs will be prolonged until the venous
phase of the contrast passage is seen[24]. The frame rate
will be set on 12,5 frames/sec. To calculate the corrected
TIMI frame count the score will be adjusted for the used
frame rate[25]. If necessary, a PCI will be carried out.
Patients are studied on a clinical 1.5 Tesla MRI scanner
within 2 to 9 days after primary PCI, and for 4-month fol-
low-up. ECG-gated cine SSFP (Steady State Free Preces-
sion) MR images are obtained during repeated breath-
holds in the three standard long axis views (four-, three-
and two-chamber view). Additional short axis slices are
acquired covering the entire left ventricle, to examine
regional and global left ventricular function.
After that i.v. injection of Gd-DTPA first-pass perfusion
imaging is performed with a saturation-recovery gradient-
echo pulse sequence. Delayed contrast-enhanced images
are acquired 10 minutes post-contrast with an inversion-
recovery gradient-echo pulse sequence to identify the
location and extent of myocardial infarction. The data are
obtained with slice locations identical to the functional
images.
Follow-up
Follow-up examination will exist from 12-lead ECG regis-
tration, 2D-echocardiography, contrast enhanced MRI,
and biomarkers of myocardial infarction (CK-MB). All
serving to achieve the secondary endpoints of this study.
MRI and 2D-echocardiography will be used to assess the
global and regional wall motion, left ventricular function,
and left ventricular ejection fraction. 12-lead ECG registra-
tion will be used to observe the ST-segment resolution
and markers to compare infarct size of both groups.
Statistical analysis
The aim of this pilot study is to investigate whether the
combination of ultrasound and microbubbles enhance
clot dissolution after pre-treatment of STEMI patients with
a loading dose of aspirin 500 mg, heparin 5000 IU, and
alteplase single bolus 50 mg.
The reason we use a single bolus alteplase is to avoid seri-
ous adverse events. The PACT-trial[26] showed there was
no difference in severe complications between the pla-
cebo group and the single bolus alteplase group after pre-
treatment with aspirin and heparin, but there still was a
significant increase in TIMI 3 flow in the alteplase group
(33%) compared to placebo (15%). With our study we are
aiming for 65% TIMI 3 flow in the group treated withPage 5 of 7
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Trials 2008, 9:72 http://www.trialsjournal.com/content/9/1/72microbubbles. In order to demonstrate this with a power
of 80% and an α of 0.05 (two sided) we need a sample
size of 29 patients per group. Therefore, we are intending
to randomize 60 patients in this pilot study.
Obtained baseline data will be presented as mean ± stand-
ard deviation (SD). Differences between the treatment
group, with ultrasound and microbubbles, and the con-
trol group in baseline data, biomarkers, 2D-echo, and
MRI variables will be assessed by unpaired students t-test.
Chi-square analyses will be conducted to observe differ-
ences in primary and secondary endpoints between the
treatment group and the control group.
All analysis will be performed based on an intention-to-
treat principle.
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PCI: percutaneous coronary intervention; SD: standard
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